


Amendment Pursuant to 37 C.F.R. § 1.121

IN THE CLAIMS:

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

1. (currently amended) A compound of formula (1):



wherein

R^1 and R^2 may be same or different and independently represent hydrogen, halogen, nitro, cyano, amino, hydroxy or optionally substituted group selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, alkylcarbonyl, alkoxy carbonyl, arylcarbonyl, aryloxy carbonyl, aralkoxy carbonyl, heteroarylcarbonyl, aryloxy, aralkoxy, alkylcarbonyloxy, alkoxy carbonylamino, aryloxy carbonylamino, aralkoxy carbonylamino, heteroarylcarbonylamino, heteroaryl, heteroarylalkyl, heterocyclyl, heteroaralkoxy, heteroaryloxy, fluorenylmethoxycarbonyl (Fmoc), fluorenylmethoxycarbonylamino (NFmoc), $-\text{OSO}_2\text{R}^8$, $-\text{CONR}^8\text{R}^9$, NR^8COOR^9 , $-\text{NR}^8\text{COR}^9$, $-\text{NR}^8\text{R}^9$, $-\text{NR}^8\text{SO}_2\text{R}^9$, $-\text{NR}^8\text{CONR}^9\text{R}^{10}$, $-\text{NR}^8\text{CSNR}^8\text{R}^9$, $-\text{SO}_2\text{R}^8$, $-\text{SOR}^8$, $-\text{SR}^8$, $-\text{SO}_2\text{NR}^8\text{R}^9$, $-\text{SO}_2\text{OR}^8$, $-\text{CONR}^8\text{R}^9$, $-\text{COOR}^9$ or $-\text{COR}^9$, wherein R^8 , R^9 and R^{10} may be same or different and independently represent hydrogen, optionally substituted group selected from alkyl, aryl, aralkyl, aryloxy or heteroaryl;

or R^1 and R^2 together represent a monocyclic or polycyclic ~~aromatic or~~ nonaromatic ring or an aromatic ring fused to a non aromatic ring or **polycyclic aromatic ring**, which may optionally contain 1 to 3

heteroatoms selected from N, S, or O and may be unsubstituted or have 1 to 4 substituents which may be identical or different;

R^3 represents hydrogen, halogen, optionally substituted group selected from alkyl, cycloalkyl, alkanoyl, aryl, aroyl, aralkyl or aralkanoyl group;

R^4 represents hydrogen, halogen, optionally substituted group selected from alkyl, cycloalkyl, alkanoyl, aroyl, aralkyl or aralkanoyl group;

'n' represents 0-6;

'p' represents 0;

X represents O, S, NR where R represents hydrogen or optionally substituted group selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, alkanoyl, or aroyl;

Ar represents optionally substituted phenyl **wherein the substituent is alkyl**;

Z represents O, S, NR where R is as defined above;

R^5 , R^6 and R^7 may be same or different and independently represent hydrogen, hydroxy, halogen or optionally substituted group selected from alkyl, cycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, heterocyclyl or heteroaralkyl groups;

or R^5 and R^6 together may form a 5 or 6 membered cyclic rings, which may contain one or two hetero atoms selected from O, S or N;

Y represents O or NR^{11} where R^{11} represents hydrogen, optionally substituted group selected from alkyl, aryl, aralkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl or heteroaryl;

or R^7 and R^{11} together may also form a 5 or 6 membered cyclic ring, which may contain one or two hetero atoms selected from O, S or N; and

'---' represents a bond or no bond;

or a stereoisomer, or a pharmaceutically acceptable salt thereof;

and

when the fused rings formed by R^1 and R^2 are substituted, the substituents are selected from alkyl, halogen, hydroxy, haloalkyl, nitro, amino, cyano, oxo, or thioxo;

when the groups represented by R^1 and R^2 are substituted, the substituents are selected from halogen, hydroxy, nitro, amino, oxo, thioxo, optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, aryl, aralkyl, alkylsulfonyl, alkylsulfinyl, alkylsulfanyl, alkylsulfonyloxy, alkylsulfinyloxy or alkylsulfanyloxy, the substituents are selected from halogen, hydroxy, nitro, amino, cyano or alkyl;

when the groups represented by R , R^3 , R^4 and R^{11} are substituted, the substituents are selected from halogen, nitro, amino, hydroxy, alkyl, oxo or aralkyl;

when the groups represented by R^5 , R^6 and R^7 are substituted, the substituents are selected from halogen, hydroxy, nitro, alkyl, cycloalkyl, alkoxy, aryl, aralkyl, aralkoxyalkyl, heterocyclyl, heteroaryl or amino;

when the cyclic rings formed by R^5 and R^6 are substituted, the substituents are selected from alkyl, halogen, hydroxy, haloalkyl, nitro, amino, cyano, oxo, or thioxo; and

the groups defined for R , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} and R^{11} may be unsubstituted, or have 1 to 4 substituents, which may be identical or different.

2. (previously presented) The compound of claim 1, wherein the stereoisomer is an enantiomer or a geometrical isomer.

3. - 5. (canceled)

6. (previously presented) The compound of claim 1, wherein:


R^1 and R^2 are same or different and independently represent hydrogen, halogen, nitro, cyano, amino, hydroxy or optionally substituted groups selected from alkyl, alkoxy, aryl, aralkyl, aralkoxy, heteroaryl, heteroaralkoxy, $-\text{OSO}_2\text{R}^8$, $-\text{SO}_2\text{R}^8$ or $-\text{NR}^8\text{R}^9$;


R^3 and R^4 are same or different and independently represent hydrogen, halogen, optionally substituted group selected from alkyl or aralkyl;

R^5 and R^6 are same or different and independently represent hydrogen, hydroxy, optionally substituted alkyl, cycloalkyl, aryl;
or R^5 and R^6 together represent a 5 or 6 membered aromatic or non aromatic cyclic ring system optionally containing 1 or 2 heteroatoms selected from O, S or N; and
 R^7 and R^{11} may form a cyclic ring system selected from pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolinyl or diazolinyl.

7. (currently amended) The compound of claim 1 wherein

R^1 and R^2 together represent an optionally substituted monocyclic or polycyclic ~~aromatic or~~ non aromatic ring or an aromatic ring fused to a non aromatic ring or polycyclic aromatic ring selected from:






8. (previously presented) The compound of claim 1, wherein:

R^1 and R^2 are same or different and independently represent hydrogen, halogen, nitro, amino, hydroxy or optionally substituted group selected from alkyl, aryl, aralkyl, aralkoxy, heteroaryl, heteroaralkoxy or $-OSO_2R^8$;
 R^3 and R^4 are same or different and independently represent hydrogen or optionally substituted alkyl; and
 R^5 and R^6 are same or different and independently represent hydrogen, optionally substituted alkyl, cycloalkyl or aryl;
or R^5 and R^6 together represent an optionally substituted 5 or 6 membered saturated cyclic ring system.

9. (currently amended) The compound of claim 1, wherein:

R^1 and R^2 together represent an optionally ~~substituted~~substituted monocyclic or polycyclic ~~aromatic or~~ non aromatic ring or an aromatic ring fused to a non aromatic ring or polycyclic aromatic ring selected from:





R^3 and R^4 are same or different and independently represent hydrogen or optionally substituted alkyl; and
 R^5 and R^6 are same or different and independently represent hydrogen, optionally substituted group selected from alkyl, cycloalkyl, aryl;
or R^5 and R^6 together represent a 5 or 6 membered saturated cyclic ring system.

10. (previously presented) The compound of claim 1, wherein:

R^1 is selected from $-\text{OSO}_2\text{CH}_3$, halogen, alkyl, optionally substituted phenyl wherein the substituent is selected from alkyl or halogen;
 R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are same or different and independently represent hydrogen, methyl, ethyl or propyl;
Ar represents optionally substituted phenyl wherein the substituent is alkyl;
X, Y and Z independently represent oxygen; and
n represents 0 or 1.

11. (previously presented) The compound of claim 1, wherein:

R^1 is selected from optionally substituted phenyl wherein the substituent is selected from halogen;

R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are same or different and independently represent











hydrogen, methyl, ethyl or propyl;


Ar represents optionally substituted phenyl wherein the substituent is alkyl;













X, Y and Z independently represent oxygen; and


n represents 0 or 1.

12. (previously presented) The compound of formula (I) as claimed in claim 1, which is selected from the group consisting of:

































13. (previously presented) The compound of formula (I) as claimed in claim 1, which is selected from the group consisting of:



















14. (previously presented) The compound of formula (1) as claimed in claim 1, which is selected from the group consisting of:



















15. (previously presented) The compound of formula (I) as claimed in claim 1, which is selected from the group consisting of:











16. (previously presented) The compound of formula (I) as claimed in claim 1, which is selected from the group consisting of:













17. (previously presented) The compound of formula (I) as claimed in claim 1, which is selected from the group consisting of:















and


18. (previously presented) The compound of formula (I) as claimed in claim 1, which is selected from the group consisting of:




and


19. (previously presented) The compound of formula (I) as claimed in claim 1, which is selected from the group consisting of:






20. (previously presented) The compound of formula (I) as claimed in claim 1, which is selected from the group consisting of:







21. (previously presented) The compound of formula (I) as claimed in claim 1, which is selected from the group consisting of:




22. (previously presented) The compound of formula (I) as claimed in claim 1, which is selected from the group consisting of:




23. (previously presented) The compound of formula (I) as claimed in claim 1, which is selected from the group consisting of:




24. (previously presented) The compound of formula (I) as claimed in claim 1, which is selected from the group consisting of:




25. (previously presented) The compound of formula (I) as claimed in claim 1, which is




26. (previously presented) The compound of formula (1) as claimed in claim 1, which is




27. (previously presented) The compound of formula (I) as claimed in claim 1, which is




28. (previously presented) The compound of formula (1) as claimed in claim 1, which is




29. (previously presented) The compound of formula (I) as claimed in claim 1, which is




30. (previously presented) The compound of formula (I) as claimed in claim 1, which is




31. (previously presented) The compound of formula (I) as claimed in claim 1, which is




32. (previously presented) The compound of formula (I) as claimed in claim 1, which is




33. (previously presented) The compound of formula (I) as claimed in claim 1, which is




34. (previously presented) The compound of formula (I) as claimed in claim 1, which is



35. (previously presented) The compound of formula (I) as claimed in claim 1, which is




36. (previously presented) The compound of formula (I) as claimed in claim 1, which is




37. - 39. (canceled)

40. (previously presented) A pharmaceutical composition, which comprises a compound of formula (I):




or a stereoisomer or a pharmaceutically acceptable salt thereof as defined in claim 1 and a pharmaceutically acceptable carrier, diluent, or an excipient.


41. (previously presented) The pharmaceutical composition of claim 40, wherein the compound is




42. (previously presented) The pharmaceutical composition of claim 40, wherein the compound is




43. (previously presented) The pharmaceutical composition of claim 40, wherein the compound is




44. (previously presented) The pharmaceutical composition of claim 40, wherein the compound is




45. (previously presented) The pharmaceutical composition of claim 40, wherein the compound is




46. (previously presented) The pharmaceutical composition of claim 40, wherein the compound is




47. (previously presented) The pharmaceutical composition of claim 40, wherein the compound is




48. (previously presented) The pharmaceutical composition of claim 40, wherein the compound is




49. (previously presented) The pharmaceutical composition of claim 40, wherein the compound is




50. (previously presented) The pharmaceutical composition of claim 40, wherein the compound is



51. (previously presented) The pharmaceutical composition of claim 40, wherein the compound is



52. (previously presented) The pharmaceutical composition of claim 40, wherein the compound is



53. (original) The pharmaceutical composition as claimed in claim 40 in the form of a tablet, capsule, powder, syrup, solution or suspension.
54. (withdrawn) A method for treating dyslipidemia in a patient comprising administering to said patient a compound of formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof as defined in claim 1.
55. (withdrawn) A method for treating diabetes caused by insulin resistance or impaired glucose tolerance comprising administering a compound of formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof as defined in claim 1.
56. - 57. (canceled)

58. (previously presented) A medicine for treating diabetes caused by dyslipidemia comprising administering a pharmaceutical composition according to claim 40 to a patient in need thereof.
59. (previously presented) A medicine for treating diabetes caused by insulin resistance or impaired glucose tolerance comprising administering a pharmaceutical composition according to claim 40 to a patient in need thereof.